119 related articles for article (PubMed ID: 10845224)
1. Absorbed dose estimates for 131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma.
Laitinen JO; Tenhunen M; Kairemo KJ
Nucl Med Commun; 2000 Apr; 21(4):355-60. PubMed ID: 10845224
[TBL] [Abstract][Full Text] [Related]
2. The effect of three dimensional activity distribution on the dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma.
Laitinen JO; Kairemo KJ; Jekunen AP; Korppi-Tommola T; Tenhunen M
Cancer; 1997 Dec; 80(12 Suppl):2545-52. PubMed ID: 9406708
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770
[TBL] [Abstract][Full Text] [Related]
5. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
Cederkrantz E; Andersson H; Bernhardt P; Bäck T; Hultborn R; Jacobsson L; Jensen H; Lindegren S; Ljungberg M; Magnander T; Palm S; Albertsson P
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):569-76. PubMed ID: 26460999
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
[TBL] [Abstract][Full Text] [Related]
7. The use of TL detectors in dosimetry of systemic radiation therapy.
Aschan AC; Toivonen MJ; Lampinen JS; Tenhunen M; Kairemo KJ; Korppi-Tommola ET; Jekunen AP; Sipilä P; Savolainen SE
Acta Oncol; 1999; 38(2):189-96. PubMed ID: 10227440
[TBL] [Abstract][Full Text] [Related]
8. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
[TBL] [Abstract][Full Text] [Related]
10. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
11. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.
van Zanten-Przybysz I; Molthoff CF; Roos JC; Plaizier MA; Visser GW; Pijpers R; Kenemans P; Verheijen RH
J Nucl Med; 2000 Jul; 41(7):1168-76. PubMed ID: 10914906
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
Stein R; Juweid M; Mattes MJ; Goldenberg DM
Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: reconstruction of a theoretical phantom of the larynx for radiation dose calculation to local tissues.
Maraveyas A; Myers M; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1020-7. PubMed ID: 7866985
[TBL] [Abstract][Full Text] [Related]
17. Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses.
Larson SM; Carrasquillo JA; Colcher DC; Yokoyama K; Reynolds JC; Bacharach SA; Raubitchek A; Pace L; Finn RD; Rotman M
J Nucl Med; 1991 Sep; 32(9):1661-7. PubMed ID: 1880565
[TBL] [Abstract][Full Text] [Related]
18. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.
Boudousq V; Ricaud S; Garambois V; Bascoul-Mollevi C; Boutaleb S; Busson M; Quenet F; Colombo PE; Bardiès M; Kotzki PO; Navarro-Teulon I; Pèlegrin A; Pouget JP
J Nucl Med; 2010 Nov; 51(11):1748-55. PubMed ID: 20956481
[TBL] [Abstract][Full Text] [Related]
19. Photon contribution to tumor dose from considerations of 131I radiolabeled antibody uptake in liver, spleen, and whole body.
Johnson TK; Colby SB
Med Phys; 1993; 20(6):1667-74. PubMed ID: 8309439
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
